Investors
Event Calendar
Upcoming Events
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
October 16, 2019
Read moreObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
October 17, 2019
Read morePast Events
ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019
October 4, 2019
ObsEva SA to present at Wedbush PacGrow Healthcare Conference – click ‘Read More’ below for webcast info
August 14, 2019
Q2 2019 ObsEva SA Earnings Conference Call: Click ‘Read More’ Below for webcast info
August 7, 2019
Sign up for news
Stock Information
Latest Press Release
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Christophe Lamps
Dynamics Group
+41 79 476 26 87
Media United States
Marion Janic
RooneyPartners LLC
+1 212-223-4017
Sign up for news
